At 13.9% CAGR, the Asia Pacific Molecular Diagnostics for Infectious Disease Market is Projected to be Worth US$ 2,360.34 Million by 2030, Says Business Market Insights

According to Business Market Insights research, the Asia Pacific molecular diagnostics for infectious disease market was valued at US$ 834.22 million in 2022 and is expected to reach US$ 2,360.34 million by 2030, registering a CAGR of 13.9% from 2022 to 2030. Rising application of molecular diagnostics in veterinary infectious diseases and surging prevalence of infectious disease globally are among the critical factors attributed to the Asia Pacific molecular diagnostics for infectious disease market expansion.

Diagnostic technologies that can detect emerging infectious animal diseases at an early stage are essential for reducing economic losses associated with outbreaks of such diseases. Polymerase chain reaction (PCR) remains the most widely used molecular assay globally for detecting animal pathogens. Diagnostic methods of this type are easy to use, cost-effective, highly sensitive, and specific, with the ability to detect at a high volume.

Point-of-care diagnostics (POCDs) are simple, rapid, and portable diagnostic devices that can detect the disease status at the field level. In recent years, real-time PCR (qPCR) has been transitioned into a POCD platform. These fully automated platforms combine nucleic acid extraction, thermal cycling, and on-site reporting results. For instance, MiniLab from Enigma Diagnostics is a molecular diagnostic platform of 10-35 kg that is carried at the field level and used for validating swine fever virus, avian influenza virus, classical swine fever virus, and foot-and-mouth disease virus for research purposes. Similarly, Boster offers Bosterbio qPCR kits to detect up to 48 individual or pooled samples. It is used for gene expression profiling, target DNA quantification, microbial detection, viral or bacterial pathogen load determination, and evaluation of primer pair performance for probe-based qPCR.

Thus, molecular diagnostics methods such as PCR and qPCR to diagnose bacterial, viral, fungal, and parasitic infections in animals can replace the conventional methods such as serological, microscopic, and culture-based techniques.

On the contrary, limitations associated with molecular testing hampers the growth Asia Pacific molecular diagnostics for infectious disease market.

Based on type, the Asia Pacific molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held 62.6% share of Asia Pacific molecular diagnostics for infectious disease market in 2022, amassing US$ 521.89 million. It is projected to garner US$ 1,446.98 million by 2030 to expand at 13.6% CAGR during 2022-2030.

The Asia Pacific molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held 94.5% share of the Asia Pacific molecular diagnostics for infectious disease market in 2022, amassing US$ 295.15 million. It is projected to garner US$ 858.67 million by 2030 to expand at 14.3% CAGR during 2022-2030. Additionally, the human testing segment, by laboratory testing, held 94.4% share of the Asia Pacific molecular diagnostics for infectious disease market in 2022, amassing US$ 492.86 million. It is projected to garner US$ 1,359.15 million by 2030 to expand at 13.5% CAGR during 2022-2030.

Based on application, the Asia Pacific molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held 45.8% share of the Asia Pacific molecular diagnostics for infectious disease market in 2022, amassing US$ 142.98 million. It is projected to garner US$ 408.80 million by 2030 to expand at 14.0% CAGR during 2022-2030. Additionally, the drug regimen selection segment, by laboratory testing, held 36.6% share of the Asia Pacific molecular diagnostics for infectious disease market in 2022, amassing US$ 191.02 million. It is projected to garner US$ 527.28 million by 2030 to expand at 13.5% CAGR during 2022-2030.

Based on disease type, the Asia Pacific molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held 64.7% share of the Asia Pacific molecular diagnostics for infectious disease market in 2022, amassing US$ 202.16 million. It is projected to garner US$ 601.54 million by 2030 to expand at 14.6% CAGR during 2022-2030. Additionally, the STDs segment, by laboratory testing, held 53.3% share of the Asia Pacific molecular diagnostics for infectious disease market in 2022, amassing US$ 278.10 million. It is projected to garner US$ 785.00 million by 2030 to expand at 13.9% CAGR during 2022-2030.

Based on infection type, the Asia Pacific molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The Point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held 48.2% share of the Asia Pacific molecular diagnostics for infectious disease market in 2022, amassing US$ 150.41 million. It is projected to garner US$ 431.68 million by 2030 to expand at 14.1% CAGR during 2022-2030. Additionally, the bacteria segment, by laboratory testing, held 47.8% share of the Asia Pacific molecular diagnostics for infectious disease market in 2022, amassing US$ 249.51 million. It is projected to garner US$ 678.94 million by 2030 to expand at 13.3% CAGR during 2022-2030.

Based on country, the Asia Pacific molecular diagnostics for infectious disease market is categorized into Malaysia, India, Indonesia, China, Japan, South Korea, and the Rest of Asia Pacific. The Rest of Asia Pacific held 27.8% share of Asia Pacific molecular diagnostics for infectious disease market in 2022, amassing US$ 231.66 million. It is projected to garner US$ 672.46 million by 2030 to expand at 14.2% CAGR during 2022-2030.

Key players operating in the Asia Pacific molecular diagnostics for infectious disease market are Abbott Laboratories, bioMerieux SA, Bruker Corp, Danaher Corp, DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc, Siemens Healthineers AG, and Thermo Fisher Scientific Inc, among others.

• In Dec 2021, Roche launched the first infectious disease tests and cobas omni Utility Channel for use on the cobas 5800 System in countries accepting the CE Mark. The launch of the cobas omni Utility Channel enables laboratory professionals the flexibility of running CE-IVD assays, as well as designing their own laboratory developed tests (LDTs). This new offering expands access to critical and robust diagnostic tools that enables healthcare providers to deliver high quality care to patients worldwide, including access to regions with the highest disease burdens.
  
  
• In Feb 2023, Thermo Fisher Scientific launched PCR kits for infectious disease detection in India. Thermo Fisher Scientific announced that its Applied Biosystems TaqPath PCR kits for infectious diseases such as multi-drug-resistant tuberculosis (MTB MDR), M. tuberculosis complex (MTB), hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and for genetic analysis (HLA B27) have received licensing rights by the Central Drugs Standard Control Organisation (CDSCO) and will be manufactured in India in association with Mylab Discovery Solutions.
  
  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com